Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

作者： Christopher J. Johnson1, Christina M. Carlson2, Aaron R. Morawski3, Alyson Manthei4, Neil R. Cashman5 1USGS National Wildlife Health Center, 2Department of Soil Science,University of Wisconsin–Madison, 3Laboratory of Immunology, National Institute of Allergy and Infectious Diseases,National Institutes of Health, 4Merial Veterinary Scholars Program, School of Veterinary Medicine,University of Wisconsin–Madison, 5Department of Neurology,University of British Columbia

简介：

Overview

This study presents an in vitro prion protein conversion assay designed to assess the species barrier of transmissible spongiform encephalopathies (TSEs) without the need for animal challenges. The assay measures the conversion efficiency ratio (CER) to evaluate the species barrier for TSE agents.

Key Study Components

Area of Science

• Neuroscience
• Prion diseases
• In vitro assays

Background

• Prion diseases pose significant challenges in interspecies transmission studies.
• Traditional methods often require animal models, which are ethically and logistically complex.
• In vitro assays can provide a more efficient alternative for studying species barriers.
• The conversion efficiency ratio (CER) is a key metric in assessing these barriers.

Purpose of Study

• To develop an in vitro assay for predicting species barriers in prion diseases.
• To eliminate the need for live animal challenges in assessing transmissible spongiform encephalopathies.
• To provide a reliable method for evaluating the risk of interspecies transmission.

Methods Used

• Preparation of two conversion assay substrates.
• Incubation of substrates with TSE agents.
• Digestion of samples with Proteinase K.
• Analysis of samples using SDS-PAGE and immunoblotting.
• Measurement of proteinase K resistant prion protein using flow cytometry.

Main Results

• The assay successfully predicts species barriers for various TSE agents.
• Conversion efficiency ratios (CER) were calculated to quantify species barriers.
• The method demonstrated reliability and reproducibility in results.
• Results suggest potential applications in risk assessment for prion diseases.

Conclusions

• The in vitro prion protein conversion assay is a promising tool for studying species barriers.
• This method reduces reliance on animal models, aligning with ethical research practices.
• Future studies may expand the applicability of this assay to other prion diseases.

Frequently Asked Questions